MoFo News Item

MoFo Advises Fulgent on IPO

04 Oct 2016

Morrison & Foerster advised Fulgent Genetics [Nasdaq: FLGT] in the closing of its initial public offering of 4,200,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts. Fulgent began trading on September 29, 2016. The offering closed on October 4, 2016.

Credit Suisse Securities (USA) LLC and Piper Jaffray & Co. served as joint book-running managers for the offering. Raymond James & Associates, Inc. served as lead manager and BTIG, LLC served as co-manager.

Fulgent is a rapidly growing technology company founded in 2011 and headquartered in Temple City, California. It is initially focused on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. Fulgent intends to use the proceeds from its IPO for working capital and general corporate purposes.

The MoFo deal team was led by San Diego partner Scott Stanton and Palo Alto partner Sara Terheggen, with assistance from San Diego associates Lisa Abbot, Shai Kalansky, and Andrew Dixon.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.